🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06000319
Enrolling by invitation Observational

Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion

NCT06000319 · tracked via the Priya Life Science USA tracker
Sponsor
Induce Biologics USA Inc.
Phase
Observational
Started
2024-01-04
Last updated
2025-11-18

Condition(s) studied

Degenerative Disc DiseaseDegenerative SpondylolisthesisSpinal Stenosis

Investigational drug(s) / intervention(s)

Natural Matrix Protein (NMP) FibersLumbar interbody fusionCervical interbody fusion

Natural Matrix Protein (NMP) Fibers: human bone allograft

Lumbar interbody fusion: Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between L1 and S1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.

Cervical interbody fusion: Procedure that involves removing the intervertebral disk from the disk space between between 2 or more vertebrae between C2 and T1. When the disk space has been cleared out, the surgeon fills the void between the vertebrae with a bone void filler.

Study summary

The aim of this study is to evaluate the effectiveness and safety of Natural Matrix Protein™ (NMP™) fibers when used in cervical or lumbar interbody fusion in patients with degenerative disc disease (DDD), spinal stenosis, spondylolisthesis undergoing cervical or lumbar interbody spine fusion at no more than 3 adjacent levels.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Subject was diagnosed with DDD, spinal stenosis, or spondylolisthesis; 2. Subject has undergone cervical or lumbar interbody spine fusion at no more than 3 adjacent levels between C2 and T1 or between L1 and S1; 3. Subject has undergone cervical or lumbar interbody spine fusion using NMP Fibers; 4. Subject must be 18 years of age or older at the time of consent; 5. Subject must be willing and able to sign an informed consent document; 6. Subject must be willing and able to return to the study clinic for all follow-up visits, agree to participate in post-operative clinical and radiographic evaluations. Exclusion Criteria: 1. Subject is under 18 years of age at the time of consent; 2. Subject is currently experiencing major mental illness (psychosis, schizophrenia, major affective disorder) which in the opinion of the investigator may indicate that the symptoms are psychological rather than of physical origin; 3. Subject is currently imprisoned.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Alabama Back Institute Jasper Alabama

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06000319 on ClinicalTrials.gov ↗ ← All trials in the USA